Cardiol hits MAVERIC enrollment target early, expands trial to 150 patients
Company pushes topline data to mid-2027 from Q1 2027 after blinded review shows fewer recurrences than expected in the Phase III pericarditis trial.
SEC filing (2)
Latest
3 stories
Wednesday, September 23
Wednesday, August 26
Cardior posts Phase 2 HF-REVERT results for CDR132L in post-MI heart failure
Tuesday, July 14
Cardiol's Phase II pericarditis data published in JAHA as Phase III MAVERIC nears full enrollment
Cardiol Therapeutics said the peer-reviewed publication supports its ongoing pivotal Phase III MAVERIC trial of CardiolRx in recurrent pericarditis.
SEC filing